Implications of Heterogeneity in Multiple Myeloma

Table 8

Summary of agents in development which may be selectively toxic to MPC.

Drug/molecule	Mechanism of action	Phase/used in combination with other agents
DZNep inhibitor	Disruption of PRC2	Preclinical
Vimodegib (GDC-0449)	Hedgehog signaling inhibitor	Phase I/after auto SCT
R0490927	NOTCH signaling inhibitor	Phase II/melphalan
MK571	MRP3 inhibitor	Preclinical/bortezomib
ATRA	Induces degradation of RARα2	Preclinical
Imetelstat	Telomerase Inhibitor	Preclinical
NK cell therapy	Cellular cytotoxicity	Preclinical

SCT = Stem cell transplant.